Oncolytics Biotech Inc. consummated its continuance from Alberta to British Columbia on March 17, 2026 at 09:01 AM Pacific Time under Certificate of Continuation C1582211. The company adopted Notice of Articles and Articles, effective upon the certificate, modifying common shareholder rights to be governed by the British Columbia Business Corporations Act instead of Alberta law.
Key takeaways
Continuance completed March 17, 2026 at 09:01 AM PT with Certificate C1582211 issued by BC Registrar of Companies.
Notice of Articles (Exhibit 3.2) lists registered office at 2700-666 Burrard St, Vancouver BC and eight directors including Jared Kelly and Bernd Seizinger.
Articles (Exhibit 3.3) effective March 17, 2026 govern shares with no maximum common shares without par value or special rights.
Shareholder rights differ from prior Alberta documents per Circular/Prospectus Annex J incorporated by reference.